Premium
High‐Grade Nucleoside Transport Inhibition Stimulates Ventilation in Humans
Author(s) -
Rongen Gerard A.,
Smits Paul,
Bootsma Gorben,
Donck Kris Ver,
Vries Albrecht,
Thien Theo
Publication year - 1995
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1995.tb04073.x
Subject(s) - ventilation (architecture) , nucleoside , pharmacology , medicine , chemistry , biochemistry , physics , thermodynamics
In 6 healthy male volunteers a placebo‐controlled, double‐blind, randomized, crossover trial was done to assess the effect of 1, 2, 4, and 6 mg of draflazine, a specific nucleoside transport inhibitor, on ventilation. Draflazine increased thoracic excursions dose‐dependently by maximally (median with 95% confidence interval) 114.0% (38.3–184.8%) without affecting breathing rate . Ex vivo adenosine transport was inhibited by 0% (0–1%) after placebo, and 70% (59–74%), 81% (76–85%), 90% (86–93%), and 93% (90–96%) after the 4 increasing draflazine dosages, respectively (P < .05 for each draflazine dosage versus placebo). These results indicate that endogenously released adenosine may play a role in the regulation of ventilation .